Literature DB >> 2312735

Familial hypobetalipoproteinemia caused by a mutation in the apolipoprotein B gene that results in a truncated species of apolipoprotein B (B-31). A unique mutation that helps to define the portion of the apolipoprotein B molecule required for the formation of buoyant, triglyceride-rich lipoproteins.

S G Young1, S T Hubl, R S Smith, S M Snyder, J F Terdiman.   

Abstract

Apolipoprotein B-100 has a crucial structural role in the formation of VLDL and LDL. Familial hypobetalipoproteinemia, a syndrome in which the concentration of LDL cholesterol in plasma is abnormally low, can be caused by mutations in the apo B gene that prevent the translation of a full-length apo B-100 molecule. Prior studies have revealed that truncated species of apo B [e.g., apo B-37 (1728 amino acids), apo B-46 (2057 amino acids)] can occasionally be identified in the plasma of subjects with familial hypobetalipoproteinemia; in each of these cases, the truncated apo B species has been a prominent protein component of VLDL. In this report, we describe a kindred with hypobetalipoproteinemia in which the plasma of four affected heterozygotes contained a unique truncated apo B species, apo B-31. Apolipoprotein B-31 is caused by the deletion of a single nucleotide in the apo B gene, and it is predicted to contain 1425 amino acids. Apolipoprotein B-31 is the shortest of the mutant apo B species to be identified in the plasma of a subject with hypobetalipoproteinemia. In contrast to longer truncated apo B species, apo B-31 was undetectable in the VLDL and the LDL; however, it was present in the HDL fraction and the lipoprotein-deficient fraction of plasma. The density distribution of apo B-31 in the plasma suggests the possibility that the amino-terminal 1425 amino acids of apo B-100 are sufficient to permit the formation and secretion of small, dense lipoproteins but are inadequate to support the formation of the more lipid-rich VLDL and LDL particles.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2312735      PMCID: PMC296513          DOI: 10.1172/JCI114522

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  41 in total

1.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

2.  Familial hypobeta-lipoproteinemia: studies in 13 kindreds.

Authors:  C J Glueck; P S Gartside; M J Mellies; P M Steiner
Journal:  Trans Assoc Am Physicians       Date:  1977

3.  Familial hypobetalipoproteinemia. Absence of atherosclerosis in a postmortem study.

Authors:  J A Kahn; C J Glueck
Journal:  JAMA       Date:  1978-07-07       Impact factor: 56.272

4.  Familial homozygous hypobetalipoproteinemia.

Authors:  C Cottrill; C J Glueck; V Leuba; F Millett; D Puppione; W V Brown
Journal:  Metabolism       Date:  1974-08       Impact factor: 8.694

5.  Prevalence of familial hyper- and hypolipoproteinemias: the Princeton School District Family Study.

Authors:  P M Laskarzewski; P Khoury; J A Morrison; K Kelly; M J Mellies; C J Glueck
Journal:  Metabolism       Date:  1982-06       Impact factor: 8.694

6.  Heterogeneity of apolipoprotein B: isolation of a new species from human chylomicrons.

Authors:  J P Kane; D A Hardman; H E Paulus
Journal:  Proc Natl Acad Sci U S A       Date:  1980-05       Impact factor: 11.205

7.  Characterization of human high-density lipoproteins by gradient gel electrophoresis.

Authors:  P J Blanche; E L Gong; T M Forte; A V Nichols
Journal:  Biochim Biophys Acta       Date:  1981-09-24

8.  Metabolic studies in an unusual case of asymptomatic familial hypobetalipoproteinemia with hypolphalipoproteinemia and fasting chylomicronemia.

Authors:  D Steinberg; S M Grundy; H Y Mok; J D Turner; D B Weinstein; W V Brown; J J Albers
Journal:  J Clin Invest       Date:  1979-07       Impact factor: 14.808

9.  Familial hypobetalipoproteinaemia in 9 children diagnosed as the result of cord blood screening for hypolipoproteinaemia in 10 000 Danish newborns.

Authors:  G E Andersen; K Brokhattingen; P Lous
Journal:  Arch Dis Child       Date:  1979-09       Impact factor: 3.791

Review 10.  Hypolipidemia.

Authors:  M J Malloy; J P Kane
Journal:  Med Clin North Am       Date:  1982-03       Impact factor: 5.456

View more
  13 in total

1.  The polymorphism ApoB/4311 in patients with myocardial infarction and controls: the ECTIM Study.

Authors:  J F Moreel; G Roizes; A E Evans; D Arveiler; J P Cambou; C Souriau; H J Parra; E Desmarais; J C Fruchart; P Ducimetière
Journal:  Hum Genet       Date:  1992-05       Impact factor: 4.132

Review 2.  Insights from human congenital disorders of intestinal lipid metabolism.

Authors:  Emile Levy
Journal:  J Lipid Res       Date:  2014-11-11       Impact factor: 5.922

Review 3.  Familial dyslipidaemias: an overview of genetics, pathophysiology and management.

Authors:  Sahar B Hachem; Arshag D Mooradian
Journal:  Drugs       Date:  2006       Impact factor: 9.546

4.  A truncated species of apolipoprotein B (B67) in a kindred with familial hypobetalipoproteinemia.

Authors:  F K Welty; S T Hubl; V R Pierotti; S G Young
Journal:  J Clin Invest       Date:  1991-05       Impact factor: 14.808

5.  Dual mechanisms for the low plasma levels of truncated apolipoprotein B proteins in familial hypobetalipoproteinemia. Analysis of a new mouse model with a nonsense mutation in the Apob gene.

Authors:  E Kim; C M Cham; M M Véniant; P Ambroziak; S G Young
Journal:  J Clin Invest       Date:  1998-03-15       Impact factor: 14.808

6.  Molecular and metabolic basis for the metabolic disorder normotriglyceridemic abetalipoproteinemia.

Authors:  D A Hardman; C R Pullinger; R L Hamilton; J P Kane; M J Malloy
Journal:  J Clin Invest       Date:  1991-11       Impact factor: 14.808

7.  Targeted modification of the apolipoprotein B gene results in hypobetalipoproteinemia and developmental abnormalities in mice.

Authors:  G E Homanics; T J Smith; S H Zhang; D Lee; S G Young; N Maeda
Journal:  Proc Natl Acad Sci U S A       Date:  1993-03-15       Impact factor: 11.205

8.  Modification of the apolipoprotein B gene in HepG2 cells by gene targeting.

Authors:  R V Farese; L M Flynn; S G Young
Journal:  J Clin Invest       Date:  1992-07       Impact factor: 14.808

9.  Expression, secretion, and lipid-binding characterization of the N-terminal 17% of apolipoprotein B.

Authors:  H Herscovitz; M Hadzopoulou-Cladaras; M T Walsh; C Cladaras; V I Zannis; D M Small
Journal:  Proc Natl Acad Sci U S A       Date:  1991-08-15       Impact factor: 11.205

10.  (Pro)renin Receptor Inhibition Reprograms Hepatic Lipid Metabolism and Protects Mice From Diet-Induced Obesity and Hepatosteatosis.

Authors:  Liwei Ren; Yuan Sun; Hong Lu; Dien Ye; Lijuan Han; Na Wang; Alan Daugherty; Furong Li; Miaomiao Wang; Fengting Su; Wenjun Tao; Jie Sun; Noam Zelcer; Adam E Mullick; A H Jan Danser; Yizhou Jiang; Yongcheng He; Xiongzhong Ruan; Xifeng Lu
Journal:  Circ Res       Date:  2018-01-04       Impact factor: 17.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.